Rani is developing an oral preparation, sugar needle capsules (Rani pills), which can convert injectable drugs into pills for oral administration.
CCHT invested $15 million to participate in the first round D financing of Rani. After taking a stake in Rani, CCHT will have the opportunity to cooperate in the development of new biological oral preparations (oral growth hormone, etc.) projects, and promote the upgrading of the pillar products (growth hormone) of GenSci, the core subsidiary of the Group, ensuring that the pillar product is technically world-leading.
At present, the project has completed the feasibility study of empty pills containing no drug through small-scale clinical trials in healthy people. This is the first time that human has swallowed a robot pill.